Skip to main content
Premium Trial:

Request an Annual Quote

Biomarker Discovery Firm Biospect Raises $27M in Financing, Appoints CEO

NEW YORK, Oct. 21 (GenomeWeb News) - Biospect, a South San Francisco, Calif.-based startup developing systems for detecting biomarker patterns, today said it has received more than $27 million in equity financing from four venture capital firms: Advent Venture Partners, Prospect Venture Partners, Venrock Associates, and Versant Ventures. 

In addition, the company said that it has appointed Deborah Neff as president and CEO. Neff, who most recently held the position of worldwide president of BD Biosciences, will also serve on Biospect's board of directors.

Jim Tananbaum, chairman of Biospect and managing partner of Prospect Venture Partners, said the company plans to use the funding to commercialize its biomarker platform, which consists of proprietary separation, detection, and informatics technologies to detect patterns that characterize distinct biological states.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.